Differences between endocrinologists and endocrine surgeons in management of the solitary thyroid nodule

Summary Background  It is not known whether management of the solitary thyroid nodule differs between endocrinologists and endocrine surgeons. Methods  A questionnaire containing a hypothetical case (a 42‐year‐old euthyroid woman with a 2‐×‐3‐cm solitary thyroid nodule) and 13 clinical variations wa...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical endocrinology (Oxford) 2007-06, Vol.66 (6), p.844-853
Hauptverfasser: Walsh, John P., Ryan, Simon A., Lisewski, Dean, Alhamoudi, Mohammed Z., Brown, Suzanne, Bennedbæk, Finn N., Hegedüs, Lazlo
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Summary Background  It is not known whether management of the solitary thyroid nodule differs between endocrinologists and endocrine surgeons. Methods  A questionnaire containing a hypothetical case (a 42‐year‐old euthyroid woman with a 2‐×‐3‐cm solitary thyroid nodule) and 13 clinical variations was sent to endocrinologists and endocrine surgeons in Australia. Results  The response rate was 51%, including 122 endocrinologists and 48 endocrine surgeons. For the index case, serum thyroid‐stimulating hormone (TSH), fine needle aspiration biopsy (FNAB) and ultrasonography were widely used by both groups, but thyroid antibody tests and scintigraphy were ordered more commonly by endocrinologists. In the setting of benign cytology, treatment differed significantly between specialties for the index case (endocrinologists: no treatment 78%, surgery 11%, thyroxine 11%; surgeons: no treatment 73%, surgery 25%, thyroxine 2%; P = 0·032). Treatment recommendations also differed significantly for 12 of the 13 clinical variations. In particular, for a patient with a suppressed serum TSH concentration, a majority of endocrinologists recommended radioiodine treatment, whereas surgeons favoured surgery (endocrinologists: radioiodine 53%, surgery 22%, no treatment 25%; surgeons: surgery 60%, radioiodine 11%, no treatment 27%; P 
ISSN:0300-0664
1365-2265
DOI:10.1111/j.1365-2265.2007.02823.x